Eli Lilly & Co
LLY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000059478
In the last 90 days, Eli Lilly & Co insiders filed 0 open-market purchases and 3 sales; 4,644 institutions reported holding it in 13F filings for Q2 2026, worth $942.8B in total; 4 superinvestors hold it, including ARK Invest and Soros Fund Management.
Q3 2023 vs. Q2 2023
How the institutions holding Eli Lilly & Co changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 2,819 | 34 | 2,979 | +194 |
| Shares | 784.5M | 1.04M | 785.6M | +2.07M (+0.3%) |
| Value | $366.7B | $486.2M | $421.9B | +$55.7B (+15.2%) |
34 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (277)
Institutions that held Eli Lilly & Co at the end of Q3 2023 but not at the end of Q2 2023.
Showing the largest 100 of 277 by value.
Sold out (83)
Institutions that held Eli Lilly & Co at the end of Q2 2023 and filed for Q3 2023 without it.
Not filed for Q3 2023 yet (34)
Institutions that held Eli Lilly & Co at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.